Immunome, Inc. (IMNM)

NCM – Цена в реальном времени. Валюта: USD

22.69

-0.31 (-1.35%)

При закрытии: May 12, 2026, 4:00 PM EDT

22.81

+0.12 (0.53%)

До открытия: May 13, 2026, 8:48 AM EDT

12.05.2026

Immunome Reports First Quarter 2026 Financial Results and Provides Business Update

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended March 31, 2026, and provided a business update. “This quarter reflects the progress we are making in building Immunome into a multi-program targeted oncology company,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome. “The NDA submission for v.

05.05.2026

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on May 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 450,000 shares of common stock to nineteen new employees under the Company's 2024 Indu.

29.04.2026

Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. “The varegacestat NDA submission marks an important milestone for Immunome. It r.

21.04.2026

Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that data from RINGSIDE, its global, Phase 3, randomized, placebo-controlled trial of varegacestat in patients with progressing desmoid tumors, has been selected for presentation in an oral abstract session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 2.

14.04.2026

Immunome (IMNM) Price Forecast: Breakout Points to Higher Highs Ahead

Immunome stock shows renewed strength after a pennant breakout, signaling a potential continuation of its recovery trend with upside momentum building toward prior highs.

04.04.2026

Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More

9,438 shares were sold for a transaction value of ~$204,000 on April 2, 2026. This sale represented 30.02% of Higgins's holdings at the time.

02.04.2026

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on April 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 188,500 shares of common stock to thirteen new employees under the Company's 2024 In.

Видео

No Data

There is no data to display

Пресс-релизы

12.05.2026

Immunome Reports First Quarter 2026 Financial Results and Provides Business Update

05.05.2026

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

29.04.2026

Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors

21.04.2026

Immunome, Inc. (IMNM)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Immunome, Inc. (IMNM)

Immunome Reports First Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors

Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting

Immunome (IMNM) Price Forecast: Breakout Points to Higher Highs Ahead

Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Immunome Reports First Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors

Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting

Immunome Reports First Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors

Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting

Immunome (IMNM) Price Forecast: Breakout Points to Higher Highs Ahead

Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Immunome Reports First Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors

Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting

Search stocks

Immunome, Inc. (IMNM)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Immunome, Inc. (IMNM)

Immunome Reports First Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors

Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting

Immunome (IMNM) Price Forecast: Breakout Points to Higher Highs Ahead

Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Immunome Reports First Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors

Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting

Immunome Reports First Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors

Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting

Immunome (IMNM) Price Forecast: Breakout Points to Higher Highs Ahead

Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Immunome Reports First Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors

Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting